Monoclonal antibody
In his President's Letter, Moshe Talpaz, MD, discusses all of the treatment progress made for hematologic malignancies.
This triplet combination is safe and effective in patients with relapsed/refractory multiple myeloma...
Adding a monoclonal antibody to a triplet treatment significantly lowered the risk of disease...
Advertisement
Zanubrutinib led to significant PFS improvements compared with bendamustine plus rituximab in patients with CLL or SLL.
The use of the CD38-directed monoclonal antibody daratumumab was associated with ocular events...
The ORR was 96%, including 92% at the level of VGPR, and the MRD negativity rate was 62%...
Advertisement
Among 37 evaluable patients, the ORR was 78%, and 27 patients had a VGPR or better...
A phase III trial of magrolimab plus azacitidine versus standard of care in TP53-mutated AML is currently ongoing.
The phase III GALLIUM study confirmed obinutuzumab plus chemotherapy as a standard of care for first-line follicular lymphoma
The study included adults with treatment-naïve and relapsed/refractory CLL or small lymphocytic leukemia.
Updated findings from the ASCEND study were presented at the 2022 ASCO Annual Meeting.
In myeloma, isatuximab plus carfilzomib and dexamethasone (Isa-Kd) resulted in clinically improved...
The median PFS with the three-drug combination was higher compared with carfilzomib and dexamethasone alone.
Drs. Voorhees and Martin debate frontline treatment for fit patients with multiple myeloma.
The results did not provide any clear benefit by adding venetoclax in patients with previously untreated follicular lymphoma.
According to results presented at ASH 2021, the triplet combination of magrolimab plus azacitidine and venetoclax was safe.
Jacob Laubach, MD, MPP, from Dana-Farber Cancer Institute, shares his thoughts.
Dr. Laubach, from Dana-Farber Cancer Institute, reviews follow-up data from the phase II GRIFFIN trial.
Dr. Daver shares results from a phase I/II study evaluating the addition of the anti-CD47 antibody magrolimab.
Advertisement
Advertisement
Editorial Board
Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine
Guillermo Garcia-Manero, MDAssociate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center
Elias Jabbour, MDExecutive Editor | DB Lane Cancer Research Fund Distinguished Professor in Leukemia Research, MD Anderson Cancer Center
Kami Maddocks, MDAssociate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University
Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center
Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch
Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.